MedTrace Logo

Use of Functional MRI to Assess Functional Hypothalamic Activation in Response to Diazoxide

NCT03566511 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2025-05-31

Study results available
· View outcomes & findings →

Summary

The goal of this study is to determine whether metabolic control centers in the brain can be activated in patients with type 2 diabetes (T2D) as compared to non-diabetic individuals. This is important since people with diabetes have inappropriately high production of glucose, which could be at least in part due to impaired activation of important brain centers.

Conditions

  • Diabetes Mellitus, Type 2
  • Glucose, High Blood
  • Glucose Metabolism Disorders (Including Diabetes Mellitus)

Interventions

DRUG

Diazoxide

Healthy and T2D participants will receive diazoxide at a dose of 4-7 mg/kg (based upon weight) between baseline MRI scan and second MRI scan.

DRUG

Placebo

Healthy and T2D participants will receive placebo between baseline MRI scan and second MRI scan.

Sponsors & Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • American Diabetes Association

    collaborator OTHER

  • Meredith Hawkins

    lead OTHER

Principal Investigators

  • Meredith Hawkins, M.D., M.S. · Albert Einstein College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-06-12
Primary Completion
2020-08-01
Completion
2020-08-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03566511 on ClinicalTrials.gov